DateJuly 11, 2017
2017 Update: Read the commitment here.
2014:The Government of Togo commits to increasing service coverage by taking into account private and associative structures offering family planning services, organizing family planning services for the benefit of isolated and marginalized groups, and improving the access of local populations to family planning methods through innovative strategies. It also commits to integrating adolescent-youth sexual and reproductive health services into the PMA (minimum package of services) of health structures and recruiting and training qualified personnel for offering quality services. The Government of Togo commits to strengthening data forecasting and management to optimize the supply chain and to promoting contraceptive product supply chain excellence.
Togo also pledges to evaluate community-based distribution of services, including injectables, by December 31, 2014, reinforce results-based mechanisms for coordination, monitoring, and evaluation, and strengthen communication around family planning, particularly for key target populations. The Government of Togo also pledges to promote family planning with advocacy tools (RAPID, religious RAPID) and to institutionalize the national campaign for family planning.
DateMay 11, 2017
May 11, 2017 Update: Pfizer Inc. and a consortium of donors—including the Bill & Melinda Gates Foundation, the Children’s
Investment Fund Foundation, the UK Department for International Development (DFID), the United States Agency for International Development (USAID), and UNFPA—are launching a public-private collaboration to broaden access to Sayana Press, Pfizer’s innovative injectable contraceptive.
Sayana Press is a three-month contraceptive in the all-in-one, single-use Uniject™ injection system developed by PATH and manufactured by Becton, Dickinson & Company. Sayana Press contains a reformulation of depo medroxyprogesterone acetate that allows it to be administered subcutaneously (subQ). The product’s design means that community health workers, pharmacists, and even women themselves can be trained to administer it (where approved by national health authorities). Sayana Press is
available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.
Sayana Press is currently being introduced, scaled-up, or piloted in more than 15 FP2020 countries, with Pfizer continuing to support additional country registrations. The donor consortium is supporting the collaboration with over US $270 million in investments between now and 2022
Sept. 16, 2015--Pfizer commits to selling Sayana® Press for US$1/dose to qualified purchasers for two years. Sayana® Press combines Depo-Provera with Uniject™, a completely self-contained one-dose injection system that eliminates the need for health workers to store medicines and syringes or measure out doses. The price agreement allows Sayana® Press to be offered to women in FP2020 countries at reduced or zero cost. Financial support is provided by the Bill & Melinda Gates Foundation (BMGF) and Children’s Investment Fund Foundation (CIFF), while in-country distribution is made possible by PATH, DFID, UNFPA, and USAID.
Pfizer is responsible for quality manufacturing of Sayana® Press, as well as obtaining registrations in key markets. Sayana® Press has been registered or has registration pending in over 10 of the 69 priority family planning markets. In addition, stakeholders have sought waivers to make Sayana® Press available in markets where there is no registration.
The consortium of public and private sector donors and aid organizations supporting this collaboration will assist with procurement and support country introductions and the delivery of Sayana® Press to health facilities. At the country level, the organizations will also work with local governments to help ensure injectable contraceptive methods are included in reproductive health plans and budgets, coordinate health worker trainings, and raise awareness about the availability of Sayana® Press.
DateOctober 31, 2016
Updated - October 2016: FHI 360 renews its commitment to expand the evidence base for family planning programming and the translation of evidence into policy and practice. In response to a lack of knowledge about the association between hormonal contraception and HIV acquisition, FHI 360 will provide evidence to support contraceptive decision-making for women at risk of HIV infection who also wish to avoid pregnancy. FHI 360 continues its commitment to make family planning more accessible through task-shifting, by conducting research and advocacy for policy change. FHI 360 will continue to work with government stakeholders in FP2020 countries to develop, implement, and monitor costed implementation plans for family planning. In addition, FHI 360 will advocate for the inclusion of family planning as an essential part of an integrated approach to development; when women and girls are able to plan the size of their families and time their pregnancies, we make progress on nearly every Sustainable Development Goal.
July 11, 2012: FHI 360 will expand the evidence base for safe and effective family planning and will translate high-quality evidence into policy and practice.
DateOctober 31, 2012
Updated - October 2016: FHI 360 increases its financial commitment, from an original pledge of US$1 million of its own resources to a renewed pledge of US$3 million. These funds will be spent to support the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options. As of the FP2020 mid-point, FHI 360 had contributed US$2.29 million of its own resources.
July 11, 2012: FHI 360 commits to allocating US $1 million of their resources through 2020 in support of the development and introduction of new contraceptive technologies that will provide women in the developing world with additional high-quality, low-cost family planning options to fill gaps and expand choice.
DateJuly 11, 2012
2012: The Children’s Investment Fund Foundation is compelled by evidence on the need to address reproductive health concerns of adolescents, as girls and young women and their children are most severely impacted by failures to access the knowledge and tools for family planning. CIFF will apply its expertise in program monitoring and impact measurement to help in the development of a robust monitoring and accountability process to help track progress toward stated Family Planning 2020 goals.
In August 2015, the Children’s Investment Fund Foundation shared an update on progress in achieving its commitments to FP2020.
DateJuly 11, 2012
The foundation will also support research and development to create new contraceptives that can better serve the needs and circumstances of more women in the poorest countries around the world.
In August 2015, the Bill & Melinda Gates Foundation shared an update on progress in achieving its commitments to FP2020.
By cultivating high-level political leadership around countries’ FP2020 commitments, the Gates Foundation and its grantees have been able to work with government to expand access to family planning in priority countries. For example: